AB Science S.AAB
▲ PositiveCapitalrelevance
Raises EUR 2.3 million via private placement, extending cash runway beyond 12 months.
Impact on stocks 1
Health Care
AB Science S.AAB Science completes EUR 2.3 million private placement
Corporate Action
AB Science has successfully completed a private placement raising EUR 2.3 million through the issuance of 3,475,758 new ordinary shares with warrants attached. The proceeds will primarily fund the AB8939 program in acute myeloid leukemia and masitinib in amyotrophic lateral sclerosis, extending the company's cash runway beyond the next 12 months. The units were priced at EUR 0.66 each, a 24.23% discount to the three-day volume-weighted average price, and each warrant entitles the holder to subscribe for one additional share at EUR 0.93 within 60 months. Following the placement, the company's share capital will consist of 73,251,991 ordinary shares, with the new shares expected to begin trading on Euronext Paris on July 6, 2026.
AB Science S.ARaises EUR 2.3 million via private placement, extending cash runway beyond 12 months.